Avalyn Pharma Prices Upsized $300M IPO at $18 Per Share
feedReported by GlobeNewswire
Sentiment
Positive
Importance
9
Price
0
Mkt Cap
0
52W Low
0
52W High
0
Market data snapshot near publication time
summarizeSummary
Avalyn Pharma has priced its upsized initial public offering of 16,666,667 shares at $18.00 per share, expecting to raise gross proceeds of $300 million. This successful capital raise, which was upsized due to strong investor demand, provides significant funding for the clinical-stage biopharmaceutical company to advance its pipeline of inhaled therapies for serious, rare respiratory diseases. The shares are anticipated to begin trading on the Nasdaq Global Select Market under the ticker "AVLN" on April 30, 2026. Traders will closely monitor the stock's performance on its market debut.
This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.